Optic Neuritis

Overview

Optic neuritis (ON) is inflammatory demyelination of the optic nerve, classically presenting with subacute unilateral vision loss accompanied by pain, particularly with eye movement. Its modern clinical identity was shaped by the Optic Neuritis Treatment Trial (ONTT), which established the natural history, visual prognosis, association with multiple sclerosis (MS), and therapeutic response to corticosteroids that formed the foundation of contemporary management.¹ Since the ONTT era, the field has shifted substantially: optic neuritis is no longer understood as a single, biologically uniform demyelinating syndrome, but rather a group of distinct disorders — MS-associated ON, aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD-ON), myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-ON), and "double-negative" ON (antibody-negative, non-MS) — each with its own immunopathology, imaging signature, and long-term prognosis.¹

Epidemiology & Risk Factors

Optic neuritis classically affects young adults, with a strong female predominance in MS-associated disease. Risk of eventual MS diagnosis after a first episode of ON correlates strongly with baseline brain MRI findings — the presence of demyelinating white matter lesions substantially raises subsequent MS risk, a relationship first quantified by the ONTT.¹ MOGAD and AQP4-NMOSD each have distinct demographic and epidemiologic profiles from MS-ON and from each other, reinforcing that "optic neuritis" risk stratification now requires antibody-specific consideration rather than a single generic risk framework.²³

Pathophysiology

MS-associated ON results from T-cell-mediated autoimmune demyelination of the optic nerve, part of the broader central nervous system demyelinating process of MS. AQP4-NMOSD-ON is mechanistically distinct: it is driven by pathogenic IgG antibodies targeting the aquaporin-4 water channel expressed on astrocytes, producing a complement-mediated astrocytopathy that causes more severe axonal injury than typical MS-ON.³ MOG-ON is driven by antibodies against myelin oligodendrocyte glycoprotein, a distinct autoimmune target from AQP4, and is associated with a demyelinating (rather than primarily astrocyte-destructive) pattern of injury that tends to produce more severe optic disc edema but generally better structural preservation and visual recovery than AQP4-NMOSD.¹²

Clinical Presentation

Patients typically report subacute (hours to days) unilateral vision loss, often accompanied by pain that worsens with eye movement (from inflammation of the nerve sheath, which is attached to the extraocular muscles). Some patients report Uhthoff's phenomenon (transient visual worsening with increased body temperature, such as with exercise or fever) and photopsias. Compared with MS-ON, MOG-ON and AQP4-NMOSD-ON more frequently present with bilateral involvement and more severe optic disc edema at onset.¹

Exam Findings

• Reduced visual acuity, ranging from mild to severe (including no light perception in severe AQP4-NMOSD-ON)
• Relative afferent pupillary defect (RAPD) in unilateral or asymmetric bilateral cases
• Dyschromatopsia, often disproportionate to visual acuity loss
• Optic disc: can appear normal (retrobulbar ON) or edematous (papillitis), with more severe or bilateral edema more suggestive of an antibody-mediated etiology (MOG-ON or AQP4-NMOSD-ON) than typical MS-ON¹
• Visual field defect, classically central or cecocentral, though any pattern can occur

Classification

Modern classification is antibody- and imaging-based rather than purely clinical:

• MS-associated ON: typically unilateral, retrobulbar or mild disc edema, MRI showing demyelinating white matter lesions typical of MS, oligoclonal bands often present on CSF analysis
• MOG-ON: frequently bilateral or with severe disc edema, longitudinally extensive optic nerve involvement with perineural/orbital fat enhancement on MRI, generally more favorable visual recovery than AQP4-NMOSD despite dramatic acute presentation¹
• AQP4-NMOSD-ON: severe vision loss with higher propensity for bilateral involvement, longitudinal optic nerve enhancement, and chiasmal involvement; high recurrence risk and significant risk of permanent visual deficit³
• Double-negative ON: antibody-negative (both AQP4 and MOG), non-MS-pattern optic neuritis — a heterogeneous category whose underlying pathogenesis remains incompletely understood¹

Differential Diagnosis

• Anterior ischemic optic neuropathy (typically painless, older patients, altitudinal field defect — see the dedicated entry on giant cell arteritis and ischemic optic neuropathy)
• Compressive optic neuropathy (orbital or intracranial mass)
• Toxic/nutritional optic neuropathy (typically bilateral, gradual, painless)
• Hereditary optic neuropathy (e.g., Leber hereditary optic neuropathy) in atypical, painless, or bilateral presentations, especially in young males
• Infectious/inflammatory optic neuropathy (syphilis, sarcoidosis)

Management

Diagnostic workup after a first episode of ON should include contrast-enhanced brain and orbital MRI (for demyelinating lesion burden, and to characterize the pattern of optic nerve enhancement), and serologic testing for AQP4 and MOG antibodies using live cell-based assays, which have significantly improved diagnostic accuracy over older assay methods.¹ Cerebrospinal fluid analysis, including oligoclonal bands, further refines diagnosis and is most supportive of an MS-associated process.¹

High-dose corticosteroids remain the mainstay of acute treatment across ON subtypes for accelerating visual recovery, though the underlying long-term management differs substantially by etiology.¹ For MOGAD specifically, high-dose corticosteroids are the mainstay of acute management, while long-term immunotherapy — intravenous immunoglobulin, rituximab, and other steroid-sparing agents — has shown efficacy in reducing relapse risk, though optimal maintenance regimens are still under investigation and treatment should be individualized.² AQP4-NMOSD-ON requires similarly urgent recognition given its high recurrence rate and significant risk of permanent visual and neurological deficits, with both short- and long-term immunosuppressive therapy central to management.³

Complications

• Permanent visual field loss or reduced acuity, particularly in AQP4-NMOSD-ON
• Recurrent episodes, especially in AQP4-NMOSD and, to a lesser extent, MOGAD
• Progression to clinically definite MS in MS-associated ON, with risk stratified by baseline MRI lesion burden
• Optic atrophy on long-term follow-up, which can be tracked structurally with OCT retinal nerve fiber layer and ganglion cell measurements

Clinical Pearls

• Optic neuritis is no longer a single diagnosis — antibody testing (AQP4, MOG) and characterization of MRI enhancement pattern meaningfully change prognosis and treatment, and should be pursued after essentially every first presentation.¹
• Bilateral involvement or severe disc edema at presentation should raise suspicion for MOG-ON or AQP4-NMOSD-ON rather than typical MS-associated ON.¹
• Despite often dramatic acute presentation, MOG-ON generally has a more favorable visual recovery prognosis than AQP4-NMOSD-ON — severity at onset does not reliably predict long-term outcome across subtypes.¹
• OCT structural biomarkers can help differentiate subtypes: severe early ganglion cell loss is more typical of AQP4-NMOSD-ON, while MOG-ON tends to show relative structural preservation despite dramatic acute disc edema.¹

Common Pitfalls

• Treating all optic neuritis as a single entity and applying ONTT-era natural history and prognosis assumptions uniformly, when these findings are most directly applicable to MS-associated (and double-negative) ON rather than antibody-mediated subtypes.
• Failing to test for AQP4 and MOG antibodies after a first ON episode, delaying recognition of a high-recurrence-risk subtype requiring different long-term immunotherapy.
• Assuming painless vision loss excludes optic neuritis — while pain with eye movement is classic, its absence doesn't rule out the diagnosis, particularly in some antibody-mediated subtypes.
• Overlooking that global disparities in access to high-resolution MRI, OCT, and cell-based antibody assays remain a real limitation to precise ON subtyping in many practice settings.¹